Clinical trials: Circulating Tumor Cells
Breast Cancer
Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, methotrexate, and prednisolone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00687648
- Testing
- anastrozole, cyclophosphamide, exemestane
- Where
- Singapore
- Volunteers
- 70 people
- Sponsor
- National Cancer Centre, Singapore
Lung Cancer, NSCLC
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
The vast majority of patients with stage I (tumors ≥ 4cm), IIA, IIB (and select stage III) NSCLC are managed with upfront surgery, followed by adjuvant chemotherapy.
- Trial name
- NCT04367311
- Testing
- Atezolizumab, Docetaxel, Cisplatin
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nasser Hanna
Colorectal Neoplasms
Invasiveness and Chemoresistance of Cancer Stem Cells in Colon Cancer
The main objective of this study is to identify and characterize subpopulations of cells with invasive capacity in colorectal cancer from primary tumor, blood and metastatic samples.
- Trial name
- NCT01577511
- Testing
- Samples and follow up
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Lung Adenocarcinoma, Stage I, Diagnoses Diseases
Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma
In 2015-2016, 224,390 cases were newly diagnosed with lung cancer in USA. Of all the cases, 83% are non-small cell lung cancer (NSCLC).
- Conditions
- Lung Adenocarcinoma, Stage I, Diagnoses Diseases, Circulating Tumor Cells, Treatment
- Trial name
- CTCs detection (NCT02951897)
- Testing
- lobectomy, segmentecomy, chemotherapy（pemetrexed+CISPLATIN）
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Third Military Medical University
Non Small Cell Lung Cancer
Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer
The purpose of this research study is to evaluate a blood test to measure circulating tumor DNA (ctDNA). It is hypothesized that ctDNA may identify patients who can be considered for additional therapy.
- Trial name
- NCT03746262
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
CTC and Tumor Related Rare Cell
Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy
The primary objective of this study is designed to evaluate the enumeration of circulating tumor cells and identify the potential biomarkers associated with clinical outcome.
- Trial name
- NCT03434912
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- MiCareo Taiwan Co., Ltd.
Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment
Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer
This pilot study aims to trial multimodal early response assessment to enable therapy adaptions in the context of non-operative therapy strategies of locally advanced rectal cancer (LARC) for development of a non-invasive…
- Conditions
- Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment, Radiotherapy, Adaptive Treatment
- Trial name
- PRIMO (NCT05524012)
- Testing
- Blood sample, MRI scan
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Jena University Hospital
Solid Tumor, Carcinoma
Propofol vs Sevo for Paediatric Tumor Surgery
Background: Retrospective studies and meta-analyses have shown a reduction in 5-year survival following inhalational based compared to propofol based total intravenous (TIVA) anaesthesia for cancer surgery.
- Conditions
- Solid Tumor, Carcinoma, Malignancy, Cancer
- Trial name
- NCT04475705
- Testing
- propofol, sevoflurane
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- Hong Kong Children's Hospital
Gastrointestinal Stromal Tumors
Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
Activating mutations of the kinases CKIT or PDGFRA can be detected in 90% of cases by DNA sequence analysis of a pathological specimen.
- Trial name
- NCT01462994
- Testing
- Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Technical University of Munich
microRNA, Circulating Tumor Cells
The Difference of microRNA and Circulating Tumor Cells in Blood Among Cancer Patients With Immunotherapy
Among the currently important biomarkers, circulating tumor cells and microRNA (miRNA) have received significant attention. The latter, also translated as micro-ribonucleic acid, is a widely present ribonucleic acid (RNA)…
- Conditions
- microRNA, Circulating Tumor Cells, Immunotherapy
- Trial name
- NCT07260370
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Chang Gung Memorial Hospital
Breast Cancer, Prostate Cancer
Enumeration and Functional Analysis of Circulating Tumor Cells for Homologous Recombination: a Prospective Single-center Study on Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to is to evaluate whether a correlation exists between functional HR status/CTC enumeration in expanded CTCs measured before treatment initiation, and Progression Free Survival (PFS) under PARPi…
- Conditions
- Breast Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- E-FACTOR (NCT07555600)
- Testing
- blood sampling, Tumor sampling
- Volunteers
- 300 people
- Sponsor
- Centre Leon Berard
Cancer, Immune System or Toxicities Suspected
Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA
The study will evaluate the detection of tumor-antigen specific immune cells in cancer patients in whom the role of the immune system is suspected.
- Trial name
- ALCYTA (NCT05354765)
- Testing
- blood sample
- Where
- 2 sites in France
- Volunteers
- 300 people
- Sponsor
- Institut Curie
Recurrence, Metastasis
The Clinical Relevance of Immune Cells and CTC in HNSCC Patients
Head and neck squamous cell carcinomas (HNSCCs) are mainly caused by tobacco, alcohol consumption and betel nut chewing and the sixth most common cancer in the world.
- Conditions
- Recurrence, Metastasis, Death
- Trial name
- NCT02420600
- Where
- Taiwan
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Non-small Cell Lung Cancer
The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy
CTC levels collected pre-surgery will be correlated with pathological samples.
- Trial name
- NCT02135679
- Testing
- Radiotherapy
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Lung Cancer, Nonsmall Cell
ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
This study aims to incorporate circulating tumor DNA (ctDNA)-minimal residual disease (MRD) to personalize the administration of consolidation toripalimab therapy in resected stage IB-IIIA non-small-cell lung cancer (NSCLC) after…
- Trial name
- CONTINUE (NCT06426511)
- Testing
- Toripalimab+Chemotherapy, Toripalimab+Chemotherapy followed by consolidation toripalimab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Non-Small Cell Lung Cancer, Lung Adenocarcinoma
Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC
The goal of this observational study is to explore whether changes in peripheral blood effector tumor antigen-specific T cells (ETASTs) can predict treatment outcomes in patients with advanced non-small cell lung cancer (NSCLC)…
- Conditions
- Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT07392073
- Testing
- Circulating Tumor-Specific T Cell Nanodetection Technology (CTT-NanoDT)
- Volunteers
- 80 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
The goal of this study is to prospectively follow the level of circulating nucleosomes in patients treated for a non-Hodgkin lymphoma and determine whether it correlates with the clinical response.
- Trial name
- EVOLITION (NCT06813573)
- Testing
- blood sampling
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Non-small Cell Lung Cancer
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
EGFR mutation positive advanced NSCLC patients with uncleared ctDNA have poor prognosis, whether they can benefit from combination therapy has not been reported.
- Trial name
- FOCUS-C (NCT05334277)
- Testing
- Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
- Where
- 26 sites in China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Lung Cancer, Lung Neoplasms
Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer
The purpose of this study is to explore the detection of circulating tumor DNA, soluble immune markers, and the evaluation of peripheral blood mononuclear cells (PBMC).
- Conditions
- Lung Cancer, Lung Neoplasms, Cancer of Lung, Cancer of the Lung
- Trial name
- NCT02410603
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Mayo Clinic
HNSCC
WGA in Platinum-refractory HNSCC Underwent Nivolumab
To choose a subgroup who could clearly benefit from Nivolumab, we are proposing a prospective observational study. Whole-genome study (WGS) analysis will be performed on archived cancer tissues from patients who were (1)…
- Trial name
- NCT03917537
- Testing
- HNSCC patients have used Nivolumab
- Where
- 2 sites in Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital